All Posts

I presented OmicXScreen, our AI/ML-driven, DNA multi-omics disease-diagnostics platform, at the AI and Data Sciences Company Showcase during PMWC 2026. The conference gave a clear technical pulse on the industry, especially across the AI and Precision Diagnostics tracks. A few observations stood out, and each reinforces the development path we're already on at OmicXHealth: The shift to whole-genome approaches. In the Precision Diagnostics track, consensus moved decisively tow

The JPM Healthcare Conference 2026. Beyond the formal sessions at the Westin Hotel, which are for clients of the firm and by invitation only, hundreds of side events, meetups, interviews, and parties unfolded within a few-mile radius. The conference is where major biotech deals are usually announced and also the place where founders network with partners and investors through events like BioTech showcase and the RESI conference. This time around, I was not actively pitching t

Over the last several months, the OmicXHealth team conducted a series of structured interviews with hepatologists, gastroenterologists, oncologists, and clinical researchers as part of the regional NSF I-Corps program through UC Berkeley. Our goal was simple: to understand clinical decision making around liver cancer screening and uncover where current approaches fall short. These conversations provided critical insight into how early detection works today and where innovatio

We’re excited to share promising early results from our collaboration with Zymo Research Corp., marking a key milestone in our journey to develop a highly accurate, affordable blood test for liver cancer detection. In this initial evaluation, Zymo sequenced a small set of 12 biobank blood samples, consisting of both early-stage liver cancer and non-cancer liver disease cases. These samples were then analyzed using OmicXHealth’s proprietary AI/ML methylation models. The outcom

After four months of pitching, refining, and learning, OmicXHealth wrapped up the SCU Bronco Ventures Accelerator (BVA7) with an incredible win at Demo Day. It was an inspiring finale to a deeply transformative journey. Participating in the BVA7 program at Santa Clara University has been both energizing and humbling. Over the course of the accelerator, we refined our vision for OmicXHealth, building an AI-powered cfDNA methylation platform for early cancer detection. With gui